Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioflor in PPI Users
NCT07852676Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of saccharomyces boulardii in dysbiosis (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Fecal Microbiome Diversity at 8 weeks. Started Jul 2024; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
dysbiosis
Beyond the preview
Go deeper on NCT07852676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852676.